School of Medicine


Showing 61-80 of 89 Results

  • Mark Pegram

    Mark Pegram

    Susy Yuan-Huey Hung Professor

    Current Research and Scholarly InterestsMolecular mechanisms of targeted therapy resistance in breast and other cancers

  • Harlan Pinto

    Harlan Pinto

    Associate Professor of Medicine (Oncology) and of Otolaryngology - Head & Neck Surgery

    Current Research and Scholarly InterestsClinical Interests: general oncology, head and neck cancer Research Interests: chemoprevention trials and combined modality approaches to head and neck cancer

  • Kavitha Ramchandran

    Kavitha Ramchandran

    Clinical Associate Professor, Medicine - Oncology

    Current Research and Scholarly InterestsMy research focuses on innovative models of care delivey to understand how to integrate primary and specialist palliative care. We also do work in palliative care education and how to scale our education to be impactful and sustainable. We are evaluating online models.

    In cancer care I do research on novel therapeutics in thoracic malignancies including immunotherapy, new targeted agents, and new sequencing of approved drugs.

  • Fauzia Riaz, M.D., M.H.S.

    Fauzia Riaz, M.D., M.H.S.

    Clinical Assistant Professor, Medicine - Oncology

    BioDr. Riaz is a medical oncologist specializing in breast cancer whose research focuses on novel therapeutics and approaches cancer care delivery for patients with breast cancer. She is currently a Clinical Assistant Professor in the Department of Medicine at Stanford University School of Medicine. Dr. Riaz completed formal research training during her fellowship, through Yale University’s Advanced Health Sciences Research program. This included training in biostatistics, research methodology, and health policy, ultimately culminating in the completion of a Master of Health Sciences. As faculty, she is an active member of the Stanford Breast Oncology Clinical Research Group, and currently serves as the Stanford site principal investigator and sub-investigator for several ongoing breast cancer clinical trials.

  • Rajat Rohatgi

    Rajat Rohatgi

    Associate Professor of Biochemistry and of Medicine (Oncology)

    Current Research and Scholarly Intereststhe overall goal of my laboratory is to uncover new regulatory mechanisms in signaling systems, to understand how these mechanisms are damaged in disease states, and to devise new strategies to repair their function.

  • Saul A Rosenberg

    Saul A Rosenberg

    Maureen Lyles D'Ambrogio Professor in the School of Medicine, Emeritus

    Current Research and Scholarly InterestsClinical Interests: Hodgkin's disease and non-Hodgkin's lymphomas Research Interests: clinical trials, clinical-pathological-biological correlations

  • Mohana Roy, MD

    Mohana Roy, MD

    Clinical Assistant Professor, Medicine - Oncology

    BioDr. Roy is a medical oncologist and a clinical assistant professor in the Stanford University School of Medicine Department of Medicine, Division of Medical Oncology. She has expertise in Lung and Thoracic cancers, but with a broad clinical interest in hematology and oncology.

    Dr. Roy became an oncologist because of her passion for patient care. She is committed to being a clinician and is focused on improving the patient experience -- from the moment a patient checks in, to how information about their care is conveyed, and how the complex process of getting cancer care can be made a bit more seamless.

    Her research interests include access to clinical trials, quality improvement and improving care delivery. In that effort, she has published on work regarding patient reported outcomes (PROs) and their use to help clinical quality efforts- including in the context of a clinical trial with an electronic PRO portal, through distress screening with the Stanford Medicine Cancer Center, and in improving access to such screening and care for patient with limited English proficiency. She is the recipient of both a clinical innovation award through Stanford and an American Society of Clinical Oncology (ASCO) Merit award.

    She is the Associate Medical Director for Quality at Stanford Cancer Center from 2022.

    Dr. Roy received her medical degree from Albert Einstein College of Medicine, and then completed residency training at Beth Israel Deaconess Medical Center. She then completed fellowship training in Hematology and Oncology at Stanford. She was chief fellow for her graduating year during fellowship as well.

  • Lidia Schapira

    Lidia Schapira

    Professor of Medicine (Oncology)

    BioI am a medical oncologist focused on breast cancer and cancer survivorship. My career goal is to improve outcomes and experiences of patients and caregivers living with and beyond cancer, and my research and scholarship have contributed to understanding and meeting the needs of the growing population of cancer survivors. My editorial work for the Journal of Clinical Oncology has given me the opportunity to shape the discourse in oncology and as Editor-in-Chief of Cancer.Net I can bring high quality information about cancer to the lay public.

  • Sumit Shah

    Sumit Shah

    Clinical Assistant Professor, Medicine - Oncology

    BioDr. Sumit Shah specializes in the management of advanced urologic malignancies such as prostate, kidney, bladder, and testicular cancers. He also serves as an investigator on numerous clinical trials, with a focus on novel immunotherapy agents. His academic interests also include digital health technologies and novel healthcare delivery services, both in the domestic and international setting. Dr. Shah graduated with distinction in biomedical engineering from Duke University, received his medical doctorate from Stanford University, and Masters in Public Health from Harvard University. He completed his internal medicine residency at the University of California, San Francisco (UCSF) where he stayed on faculty for one year before returning to Stanford for his fellowship training in medical oncology, where he now serves on the faculty.

  • Shagufta Shaheen

    Shagufta Shaheen

    Clinical Assistant Professor, Medicine - Oncology

    BioDr. Shaheen specializes in the gastrointestinal malignancies and she has expertise in treating neuroendocrine tumors (NETs). Following her fellowship in Hematology and Oncology, Dr Shaheen completed an advanced fellowship in Neuroendocrine tumors from Stanford University. The NET advanced fellowship is first of its kind in United State started under the leadership of Dr Pamela Kunz who is the founding Director of the Stanford Neuroendocrine Tumor Program established in 2015. After completing her advanced fellowship, Dr Shaheen joined Stanford Oncology division as Clinical Assistant Professor. Dr Shaheen is involved in further developing the neuroendocrine oncology program at Stanford which serves as a centre of excellence in the treatment of neuroendocrine tumors. Dr Shaheen is actively involved in clinical research and clinical trials. Dr Shaheen is also involved in taking care of patients admitted to the oncology service as well as resident and fellow teaching.

  • Mohammad Shahrokh Esfahani

    Mohammad Shahrokh Esfahani

    Instructor, Medicine - Oncology

    BioMy expertise is in developing machine learning tools for high dimensional data. In particular, I develop Bayesian models, where 'prior knowledge', from external sources or inherent to the data set in hand, can be converted into mathematical terms (i.e. prior probabilities). I have recently focused on analyzing genetic and epigenetic signals in cell-free DNA assays. Traditional (computational) methods in cancer genomics are limited when signal to noise ratio is ultra-low which is often the case in cfDNA analyses. Therefore, there is a growing need to develop novel and more powerful methods to overcome this limitation.

  • Branimir I. Sikic, M. D.

    Branimir I. Sikic, M. D.

    Professor of Medicine (Oncology), Emeritus

    Current Research and Scholarly InterestsResearch Interests: cancer pharmacology, mechanisms of resistance to anticancer drugs, regulation and function of MDR1 and tubulin genes, CD47 as a target for activation of anticancer macrophases, Phase I trials of new drugs, gene expression profiling of cancers